A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
(OVAL Trial)
Recruiting in Palo Alto (17 mi)
+93 other locations
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
Research Team
Eligibility Criteria
Inclusion Criteria
Histologically confirmed epithelial ovarian cancer and documented disease.
Patients must have platinum-resistant disease
ECOG PS 0-1.
See 6 more
Treatment Details
Interventions
- Paclitaxel (Anti-microtubule agent)
- VB-111 (Virus Therapy)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1Experimental Treatment1 Intervention
VB-111 + Paclitaxel
Group II: Arm 2Active Control1 Intervention
Placebo + Paclitaxel
Paclitaxel is already approved in Canada for the following indications:
Approved in Canada as Paclitaxel for:
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- Kaposi's sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vascular Biogenics Ltd. operating as VBL Therapeutics
Lead Sponsor
Trials
12
Recruited
1,700+
GOG Foundation
Collaborator
Trials
48
Recruited
18,500+